We are a team of AI experts and scientists applying advanced computational methods to solve critical challenges in pharmaceutical discovery and development.
Founded in February 2025, PathoscribeAI was started by a group of AI specialists with a shared, strong interest in healthcare. Our founding principle was simple: advanced computation could dramatically improve and accelerate the long, costly process of drug development.
Our team combines deep expertise in machine learning, computational biology, and software engineering to build our intelligent platform. This system is designed to analyze complex datasets—from molecular structures to clinical trial results—to identify promising therapeutic candidates and novel biological targets.
We are driven by the challenge of applying technology to solve complex medical problems, both by finding new uses for existing medicines and by discovering new molecules for the treatments of the future.
Our core mission is to accelerate therapeutic discovery. We utilize advanced AI for both de novo drug design and high-throughput screening of repurposed compounds, aiming to shorten the R&D lifecycle and enhance preclinical success rates.
By applying in-silico analysis to complex biological data, we help pharmaceutical partners optimize their development pipelines and unlock the full potential of their molecular data assets.
We envision a future where AI-driven pharmacology is the standard, fostering an ecosystem of rapid innovation that expands the global therapeutic arsenal and streamlines the path from lab to clinic.
Our goal is to become the global leader in AI-powered drug discovery, playing a pivotal role in tackling critical diseases and fundamentally improving health outcomes for patients worldwide.
Key milestones that have shaped our progress and defined our path forward.
Our company timeline is currently being updated. Please check back soon.
We are committed to the highest standards of quality, security, and compliance.
Our certifications are currently being updated. Please check back soon.
Our team's strength lies in its expertise across artificial intelligence and biomedical science.
Meet the founding team driving PathoscribeAI's product vision, scientific execution, and market growth.
Founder & CTO
Pratap Singha leads PathoscribeAI's technology strategy and product architecture, with a strong focus on scalable AI systems for drug discovery and biomedical data intelligence. He drives platform engineering, model integration, and technical execution across the company's core solutions.
Co-founder & CEO
Ashutosh Routh shapes the company's strategic direction, partnerships, and growth roadmap. He works at the intersection of business development and product vision, ensuring PathoscribeAI delivers commercially relevant AI solutions for healthcare, pharma, and research organizations.
Co-founder & COO
Soumya Ranjan Acharya oversees operations, delivery planning, and cross-functional coordination across the organization. He focuses on execution excellence, process design, and translating strategic goals into reliable day-to-day operational outcomes.
Co-founder & CMO
Samarth Vaishnav leads PathoscribeAI's market positioning, brand communication, and growth marketing initiatives. He focuses on building a professional market presence, communicating product value clearly, and expanding the company's reach across high-intent industry audiences.